Gallbladder Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials
• Forums

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
Condition:   Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Interventions:   Drug: tislelizumab+lenvatinib+GMOX;   Drug: tislelizumab+GEMOX Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials